https://www.selleckchem.com/pr....oducts/gilteritinib-
61), psychiatric symptomatology (RR=1.44) and (mild) challenging behaviours (RR=4.58). Further efforts are needed to provide adequate mental health care, specifically to improve PM treatment regarding amount, indication and the consideration of non-psychopharmacological treatment options. Further efforts are needed to provide adequate mental health care, specifically to improve PM treatment regarding amount, indication and the consideration of non-psychopharmacological treatment options. There is lack of evidence and resear
Like
Comment
Share
